Cardiovascular disease
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 50 years or older Active donor (two or more donations in year before inclusion) One or more cardiovascular risk factor (smoker, obesity BMI 30 or higher, hypertension or antihypertensive medication, hypercholesterolemia or statin use, type 2 diabetes or medication, family history of cardiovascular disease before 65 years
Exclusion criteria
Exclusion criteria: Donors that do not master the Dutch language will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study endpoint is incidence of cardiovascular disease, comprising both CHD and HF events. This endpoint is defined as cardiovascular death, or a hospital admission for an acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), or newly diagnosed HF. The main study parameters are the blood biomarkers, these will be determined batch wise after all blood samples are collected. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study endpoints will include the individual components of the primary endpoint (cardiovascular death, non-fatal CHD, myocardial infarction, hospitalization for newly diagnosed HF) and combinations thereof, as well as all-cause mortality. Secondary study endpoints will also include a variety of donation-related endpoints (e.g. iron and protein deficiencies), neurological disorders (including dementia and stroke), cancers (including breast cancer, colon cancer, prostate cancer), haematological disorders, kidney disorders, pulmonary disorders, gastrointestinal diseases and liver disorders. | — |
Countries
Netherlands
Outcome results
None listed